[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-nsclc":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100611634","long-terms-responders-in-metastatic-lung-cancer-better-understanding-for-better-management-lungevity-study-100611634",false,"NCT07243132","Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)","Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)","LUNGEVITY","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).\n* Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance\n\nExclusion Criteria:\n\n* Difficulties for understanding French\n* Patients undergoing treatment with cytotoxic chemotherapy\n* Patients under legal guardianship, under curatorship or tutorship\n* Insufficient cognitive capacity to answer questions\n* Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)\n* Patients refusing the collection of their data (an information sheet will be provided)","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.\n\nParticipants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.\n\nThey will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.",[25,26,27],"Metastatic Lung Cancer","Metastatic NSCLC","Metastatic Small Cell Lung Cancer",[29,30,26,31],"long-terms responders","Mestastatic Lung Cancer","Metastatic small cell lung cancer","RECRUITING","2026-04-24",{"date":35,"type":36},"2026-04-27","ACTUAL",{"date":38,"type":36},"2025-07-02",{"date":40,"type":21},"2031-01-31",{"name":42,"class":43},"GFPC Investigation","OTHER",46,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100458875","phase-2-de-escalation-immunotherapy-maintenance-duration-trial-for-stage-iv-lung-cancer-patients-with-disease-control-after-chemo-immunotherapy-induction-100458875","NCT05255302","De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","DIAL","Inclusion Criteria:\n\n1. Signed Written Informed Consent:\n\n   * Subjects must have signed and dated an IRB\u002FIEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.\n   * Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n2. Patients with histologically confirmed metastatic NSCLC (Stage IV accordingly to 8th classification TNM, UICC 2015). A cytologically-proven NSCLC is allowed if a cytoblock has been prepared.\n3. PD-L1 tumor content as assessed locally by the investigator center.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n5. Weight loss\\\u003C 10% within 3 months of study entry.\n6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease.\n7. Age≥ 18 years, \\\u003C75 years\n8. Life expectancy \\> 3 months\n9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria\n10. The Investigator must confirm prior to enrolment that the patient has adequate tumor tissue available. Tumor biopsy should be exploitable for molecular analysis. If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT.\n\n    Note: Tumor tissue collected after the patient was diagnosed with metastatic disease is preferred.\n\n    Tumor tissue sample must not be from locations previously radiated. Tumor sample must be 1 block or at least 7 unstained slides of analyzable tissue.\n11. Adequate biological functions:\n\n    Creatinine Clearance ≥ 45 mL\u002Fmin (Cockcroft or MDRD or CKD-epi); neutrophils≥ 1500\u002Fmm3 ; platelets ≥100 000\u002Fmm3 ; Hemoglobin≥ 9g\u002FdL ; AST and ALT\\\u003C 3x ULN, total bilirubin \\\u003C 2xULN (patients with hepatic metastases or Gilbert's syndrome must have AST and ALT ≤ 5 x ULN and a baseline total bilirubin ≤ 2xULN).\n12. Women of childbearing potential (WOCBP) and sexually active should use an efficacious contraception method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) prior to the start of study drug.\n13. For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 6 months following the last dose.\n14. Patient has national health insurance coverage.\n\nExclusion Criteria:\n\n1. Small cell lung cancer or tumors with mixed histology including a SCLC component.\n\n   Note : Sarcomatoid histology is allowed. Neuro-endocrine large cell lung cancer with molecular features of small-cell lung cancer (i.e; Rb loss associated with TP53 mutation) will not be eligible. Other neuro-endocrine large cell subtypes, i.e. with adenocarcinoma features (STK11 or K-Ras mutations) will be eligible. In case of doubt, please contact the sponsor.\n2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A\u002FS mutation in exon 18, exon 20 insertion) or HER2 exon 20 insertion (either tissue or plasma cfDNA mutation).\n3. Known ALK, ROS1, Ret, NTRK, NRG1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS (ADN or ARN) sequencing by local genetics and\u002For pathology laboratory.\n4. Previous or active cancer within the previous 3 years (except for treated carcinoma in situ of the cervix, or basal cell skin cancer treated or not). Patients with a prostate adenocarcinoma history within the previous 3 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (≤T2a, score de Gleason ≤ 6 and PSA ≤ 10 (ng\u002Fml)) provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy).\n5. Superior vena cava syndrome persisting despite VCS stenting.\n6. Radiotherapy needed at initiation of tumour treatment, except bone palliative radiotherapy on a painful or compressive metastasis, respecting 1 week delay between the end of radiotherapy and the beginning of treatment\n7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 2 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol infusions, are allowed.\n8. History of previous primary immunodeficiency, organ transplantation needing an immunosuppressive treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3\u002F4) by immune mechanism linked to another immunotherapy treatment.\n9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.\n10. History of active autoimmune disease including but not limited to rheumatoid polyarthritis, myasthenia, autoimmune hepatitis, systemic Lupus, Wegener's granulomatosis, vascular thrombosis associated with antiphospholipid syndrome, Sjogren's syndrome with interstitial pulmonary disease, recent Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n    Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) or benign rheumatoid polyarthritis not needing any immunosuppressive systemic treatment, or benign sicca syndrome (Sjogren) without interstitial pulmonary disease, or history of past Guillain-Barre syndrome, totally reversible with no sequelae, no systemic immunosuppressive treatment during the last 20 years, are allowed to be included.\n11. Active inflammatory intestinal disease (Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea.\n12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included. Past primary pulmonary tuberculosis in youth does not consist of a contra-indication. Past tuberculosis disease history does not consist of a contra-indication provided the patient was treated during at least 6 months by anti-tuberculosis antibiotic treatment.\n13. Known HIV infection\n14. Living attenuated vaccine received within the 30 previous days\n15. Previous treatment with anti-PD-1, anti-PD-L1, Anti-CTLA4 or any ICI antibody\n16. Previous treatment with chemotherapy for lung cancer. However, if a patient has a lung adenocarcinoma, previous cisplatin treatment for another cancer type with squamous histology (Head and Neck, bladder) may be allowed provided the sponsor accepts, and provided blood tests are normal (see above).\n17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction within the previous 6 months), history or stroke within the 6 previous months. Patients with a significant cardiac history, even if controlled, should have a LVEF \\> 50%.\n18. Pre-existing moderate or severe lung interstitial disease as assessed by the diagnosis CT-scan.\n19. Inability to comply with study and\u002For follow-up procedures for family, social, geographic or psychological reasons.\n20. Pregnant, lactating, or breastfeeding women.\n21. Patients deprived of liberty by judicial or administrative decision\n22. Patient who is subject to legal protection or who is unable to express his will","74 Years",{"count":55,"type":21},1360,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials.\n\nThe aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.",[26],[63,51,64,65],"IFCT","NSCLC","Immunotherapy duration","2025-03-26",{"date":68,"type":36},"2025-04-01",{"date":70,"type":36},"2022-05-02",{"date":72,"type":21},"2029-06-01",{"name":74,"class":43},"Intergroupe Francophone de Cancerologie Thoracique",44,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100375602","tumoral-bone-strength-assessment-by-numerical-simulation-using-quantitative-ct--the-mekanos-study-100375602","NCT04170634","Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study","Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT (Computed Tomography) : the MEKANOS Study","MEKANOS","Inclusion Criteria:\n\n* Adult patients (\\> 18 years of age).\n* Patients who do not object to participating in the study. For patients participating to the biological collection: signature of the written informed consent..\n* Patients with secondary tumor lesion(s) of mammary or pulmonary non-small cell, renal, bladder, thyroid or myeloma bone origin.\n* Existence of a CT scan focused on the target lesion (or which will be performed as part of the care), performed within a time window of 30 days before and 20 days after inclusion, as part of the patient's usual bone management.\n* Target location: upper end of the femur (1\u002F3 proximal) and\u002For vertebrae. Several locations are possible for the same patient, provided that the inclusion criteria are met for each target.\n* Size of target lesion: either diffuse permeative or \\> 15 mm in size.\n* Exposure to systemic bone therapy for 3 months or less (daily clodronate or denosumab, zoledronic acid, monthly pamidronate) is allowed\n* Patients who received previous systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) are eligible.\n\nExclusion Criteria:\n\n* Patients who have received targeted treatment at the target location either in the form of radiotherapy, surgery or interventional radiology (cementoplasty, cryotherapy, radiofrequency).\n* Fractured pathological target bone.\n* For the femur target, the patient must not have a hip prosthesis on either side (target or contralateral)\n* Patients under trusteeship.",{"count":85,"type":21},220,"Osteolytic bone metastases and myeloma bone lesions are responsible of long bone and vertebral fractures leading to restricted mobility, surgery and medullar compression that severely alter quality of life and that have a huge medico-economic impact. It has been estimated that 50% of the patients with bone metastasis will encounter bone complications. In the recent years, Bone Oncology Multidisciplinary Meetings have been developed to optimize bone metastases management for each patient in harmony with oncology program.\n\nThe assessment of the fracture risk of bone metastasis remains fairly empirical and is based on simple radiography. The Mirel's score for long bones is focused on the extent of cortical defect caused by bone metastasis to identify high-risk patients at risk of fracture during surgery. It is old, little used in routine and lacks sensitivity and specificity. The SINS (Spinal Instability Neoplastic Score) score is the reference for vertebrae. Today, most patients with fracture-risk bone metastasis benefit from a lesion-centered CT scan to better characterize its extent and position but the interpretation remains qualitative. Metastases are considered as an air cavity and the mechanical properties of the tumor are not evaluated. However, many other parameters from the CTscan are available such as cortical or trabecular compartment densitometry, cortical thickness, tumor volume, and position of lysis in the bone.\n\nBased on experience acquired by the service in the evaluation of bone mechanical strength on benign bones, the investigator aim at integrating in the numerical simulation the mechanical properties of both bone and tumor, in order to evaluate the mechanical strength of the pathological bone using a numerical simulation model (finite element analysis-FEA).\n\nMEKANOS will enroll patients with bone metastases of breast, lung, kidney, thyroid or bladder cancer and myeloma lesions affecting the vertebrae or the upper end of the femur.\n\nThe resistance obtained will be compared to that of an intact bone. The best predictive parameters of mechanical strength (position of lysis, tumor nature, and bone architecture) will be then determined. Finally, the added value of this technique in relation to historical fragility scores (Mirel's and SINS scores) will be assessed.\n\nThe ultimate goal is to provide tools to assess fracture risk and improve the preventive management of bone metastases in harmony with the referring oncologist",[88,89,26],"Metastases to Bone","Metastatic Breast Cancer",[91,92,93,94],"osteolytic secondary tumoral lesion","femur","vertebrae","qCT routine imagery","2024-12-11",{"date":97,"type":36},"2024-12-16",{"date":99,"type":36},"2019-11-28",{"date":101,"type":21},"2026-11-28",{"name":103,"class":43},"Hospices Civils de Lyon",12,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100465349","patients-whole-process-follow-up-managementhope-1-100465349","NCT05339568","Patient's Whole Process Follow-up Management(HOPE-1)","A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced\u002FMetastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform","HOPE-1","Inclusion Criteria:\n\n1. Fully understand the research and voluntarily sign the informed consent form (ICF)\n2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.\n3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).\n4. According to the 8th edition of the American Joint Committee on Cancer \\[AJCC\\], it is classified as stage IIB, stage III, stage IV NSCLC.\n5. Not suitable for radical treatment or refuse surgery.\n6. The life expectancy is not less than 3 months.\n7. Be able to use a smartphone.\n\nExclusion Criteria:\n\n1. Patients with mental illness.\n2. Presence of any other malignant tumor.\n3. Patients who are expected to undergo radical surgery.\n4. Currently participating in clinical trials.\n5. Subjects who judged by the investigator to be unsuitable to participate in the trial.",{"count":114,"type":21},1268,"Our project is going to explore whether management and follow-up of locally advanced\u002Fmetastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.",[117,26],"Locally Advanced Non-Small Cell Lung Cancer","2022-09-05",{"date":120,"type":36},"2022-09-08",{"date":122,"type":36},"2022-05-22",{"date":124,"type":21},"2030-08-20",{"name":126,"class":43},"Qianfoshan Hospital",1]